The U.S. startup Surge Therapeutics has raised $32 million in a Series B round to bankroll the development of a hydrogel-based immunotherapy delivered during cancer surgery.
SURGE Therapeutics Raises $32M Series B Financing to Advance Intraoperative Immunotherapy to Improve Cancer Patient Survival Outcomes Post-Surgery streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.